Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
  • TSX Biotech Stocks To Watch (TSX.V: QPT) (TSX:ONC; NASDAQ:ONCY) (TSX.V:IMV) (AEZS) (TSX: AEZ).; Innovative Ovarian Cancer Treatments 0 comments
    Mar 26, 2014 11:26 AM | about stocks: QPTFF, ONCY, AEZS

    New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline. Stocks mentioned include Quest PharmaTech Inc. (TSX.V: QPT), Oncolytics (TSX:ONC; NASDAQ:ONCY) , Immunovaccine, Inc. (TSX.V:IMV) and Aeterna Zentaris Inc. (AEZS) (TSX: AEZ).

    There are 17,000 women living with ovarian cancer in Canada. It is estimated that this year in Canada, 2,600 women will be newly diagnosed with ovarian cancer. Ovarian cancer is the 5th most common cancer for women and is the most fatal women's cancer, says Ovarian Cancer Canada.

    According to reported statistics, more than 22,000 women are diagnosed with ovarian cancer in the United States annually, and more than 12,000 die each year.

    In February news reports said, "As many as one in four hundred women test positive for the BRCA-1 gene, often called the "breast cancer gene."

    They have not only a significantly increased risk for breast cancer, but also for ovarian cancer."

    http://www.wlbz2.com/story/news/nation/2014/03/23/6788983/

    Leading U.S. biotech stocks have had a massive bull run this year, although recently the sector has had a correction on concerns of valuations. However some of the smaller microcap stocks have not seen the same volatile trading patterns.

    For investors looking at TSX biotech stocks and life sciences stocks, a recently released interview in the Life Sciences Report (TSLR) with Roadmap Capital explains the difference in valuations in US and TSX biotech stocks best.

    "TLSR: Why invest primarily in Canadian companies? If you were exclusively a resource investor, and looking for deep value as well as growth, this is understandable, but in the life sciences sector, where the goal is huge growth, why limit yourself to Canadian stocks? Is it about tax advantages? National pride?

    HC: I should point out that the new fund has made investments in the U.S. already, and will continue to do so. But we are focusing primarily in Canada. Frankly, it's about where we see the best opportunities and risk/reward ratio. There's no shortage of innovation in Canada, but the long, drawn-out bear market that the Canadian tech and healthcare sectors went through for much of the last decade has left many interesting companies valued at levels far below what is available in other countries. To give you an example, we're putting money into a company with a $2.5M pre-money valuation. Comparable companies in the States would be valued in the $30-40M pre-money range currently. And we have invested a small amount of money into a private stem cell company called Hemostemix. It is raising money at a $25M pre-money valuation, when its best public comparables in the U.S. trade at valuations in the $200-400M range. It comes down to where we see the best valuation opportunities and risk/reward for our investors right now. - "

    Source : www.equities.com/editors-desk/stocks/hea... cPhase 2 biotech tsx ovarian cancer co's

    Sector Snapshot : Ovarian Cancer Treatment

    Quest PharmaTech Inc.'s ( TSX.V: QPT).lead product, Oregovomab is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients.

    From a previous interview with Investorideas.com, Madi R. Madiyalakan, Ph.D., Chief Executive Officer, said "Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. We are also initiating a clinical trial using Oregovomab in combination with an immuno-adjuvant, Hiltonol® (TLR3 agonist), with standard chemotherapy. Oregovomab is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers. "

    Six month chart:

    Investorideas.com Newswire

    Oncolytics (TSX: ONC; NASDAQ:ONCY)

    Oncolytics Biotech Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company's lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications. Ovarian cancer : OG-0186H (NCI / GOG Trial) Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel for Patients with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer US- status is ongoing.

    Six month chart:

    Investorideas.com Newswire

    Immunovaccine, Inc. (TSX.V: IMV)

    According to the company's financial report released March 17th, "During 2013, scientists provided compelling evidence that the human immune system could be trained to destroy cancer cells," said Dr Marc Mansour, chief operating officer. "These findings support the idea that immunotherapies have the potential to shift cancer from a life threatening disease to a chronic and manageable condition.

    "Several large pharmaceutical companies also announced during the year that vaccines will play an important role in the development of their cancer therapy programs. These industry trends parallel our own approach to the development of therapeutic cancer vaccines. With our planned trials in ovarian cancer, glioblastoma and breast cancer expected to begin this year, IMV is well placed to participate in this rapidly evolving industry."

    Highlights of 2013 and First Quarter of 2014

    • DPX-Survivac - Positive data from Immunovaccine's completed Phase I study were presented at multiple venues throughout the year, including the 2013 ASCO annual meeting. We believe that these findings represent some of the strongest immune responses against a cancer target seen to date.

    Based on these promising data, Canada's NCIC Clinical Trials Group (NCIC) agreed to sponsor and conduct a randomized Phase II study of DPX-Survivac in patients with advanced ovarian cancer. We expect this study to be initiated in 2014 with results available in 2017. Immunovaccine also signed an agreement with the University of Rome for a multicenter Phase II study of DPX-Survivac in glioblastoma patients. The study is expected to begin in 2014 and its costs will be assumed by this University.

    • DPX-0907 - Immunovaccine agreed to allow use of DPX-0907 in a Phase I/II study of breast and ovarian cancer patients at the Busto Arsizio Hospital in Italy. The study, which will be funded by Busto Arsizio, is expected to be initiated in 2014.

    Six month chart :

    Investorideas.com Newswire

    Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is a biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. Their pipeline includes Zoptarelin doxorubicin for Ovarian and prostate cancer, currently in Phase 11. Zoptarelin doxorubicin is a targeted cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by the LHRH receptor-positive tumors. The binding of conjugate molecule zoptarelin doxorubicin to cancerous cells that express these receptors results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be more effective and have less side-effects than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.

    Six month chart

    Investorideas.com Newswire

    TSX Life Sciences Snapshot

    Life Sciences Markets at a Glance - YTD February 28, 2014

    February 2014

    TSX Venture (TSXV)

    TSX

    TSXV and TSX

    Number of Issuers

    69

    39

    108

    QMV (C$)

    2,153,038,500

    63,319,048,526

    65,472,087,027

    New Listings

    2

    -

    2

    Equity Capital Raised (C$)

    126,738,564

    10,823,900

    137,562,464

    Number of Financings

    18

    2

    20

    Volume Traded

    295,773,521

    238,949,246

    534,722,767

    Value Traded (C$)

    162,114,369

    3,263,237,459

    3,425,351,827

    # of Trades

    82,324

    277,538

    359,862

    http://www.tmx.com/en/listings/sector_profiles/life_sciences.html

    According to the TSX, nearly $3 billion of equity capital was raised by life sciences companies on TSX and TSXV in 2013.

    About InvestorIdeas.com:

    InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.

    Sign up for our free news alerts

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member http://www.investorideas.com/membership/

    Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.

    More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

    Global investors must adhere to regulations of each country.

    800-665-0411 - Source - www.Investorideas.com

    Themes: biotech, pharma Stocks: QPTFF, ONCY, AEZS
Back To Investorideas.com's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.